GCM
RCKT icon

Graham Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Graham Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,743
Closed -$259K – 1447
2025
Q4 		$259K Sell
73,743
-59,769
-45% -$205K 0.01% 932
2025
Q3 		$435K Sell
133,512
-104,738
-44% -$330K 0.01% 670
2025
Q2 		$584K Buy
238,250
+227,100
+2,037% +$1.15M 0.01% 758
2025
Q1 		$74.4K Buy
+11,150
New +$110K ﹤0.01% 1224
2022
Q4 		– Sell
-68,126
Closed -$1.09M – 1292
2022
Q3 		$1.09M Buy
68,126
+4,759
+8% +$74.3K 0.04% 449
2022
Q2 		$871K Buy
63,367
+5,522
+10% +$65.8K 0.04% 483
2022
Q1 		$917K Buy
+57,845
New +$999K 0.03% 338

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Graham Capital Management's RCKT Position: Q1 2026 in Review

Graham Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 73,743 shares — an estimated $259K sold.

Graham Capital Management first reported a position in RCKT in Q1 2022 and held it in 7 quarters. The position peaked at $1.09M in Q3 2022. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Graham Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 73,743 Rocket Pharmaceuticals shares in Q1 2026, an estimated $259K.
  • Graham Capital Management first reported a position in Rocket Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Graham Capital Management's Rocket Pharmaceuticals position peaked at $1.09M in Q3 2022.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.